An outrageous abuse of the system that left Canadian patients without access
When a physician licensed in one province but residing in another country writes seventeen thousand prescriptions in three months, the resulting flood of medication across a border reveals something older than any single scandal: the tension between open systems built on trust and the human capacity to exploit them at scale. Canada's health minister has called the scheme outrageous, and regulators have moved swiftly to suspend the doctor's licence, but the deeper question now before federal and provincial officials is whether the laws governing essential medicines were ever designed for a world where geography, demand, and digital convenience converge so easily. The Ozempic shortage affecting Canadian diabetic patients has given this regulatory gap a human face.
- A Texas-based doctor used a Nova Scotia medical licence to write 17,000 Ozempic prescriptions in just three months, funnelling the drug southward while Canadian patients went without.
- Federal Health Minister Jean-Yves Duclos called the operation 'outrageous,' signalling that the government views this not as a minor irregularity but as a systemic failure demanding urgent correction.
- The College of Physicians and Surgeons of Nova Scotia moved quickly to suspend the doctor's licence on an interim basis, cutting off the prescription pipeline at its source.
- Federal and provincial health officials are now convening to examine the Food and Drugs Act for loopholes that allowed bulk medication exports to proceed undetected for months.
- For Canadians already struggling to find Ozempic for diabetes management, the case has sharpened a painful irony: a drug in short supply at home was being mailed abroad in industrial quantities.
A physician licensed in Nova Scotia but living in Texas spent three months writing 17,000 prescriptions for Ozempic, a diabetes and weight-loss drug already in short supply across Canada. Two British Columbia pharmacies filled the orders, and the medication was mailed directly to American patients. When federal Health Minister Jean-Yves Duclos learned of the scheme, he described it as an outrageous abuse of the system.
The operation only came to light when B.C. and Nova Scotia health officials began comparing notes and recognized the pattern. Their response was swift: the College of Physicians and Surgeons of Nova Scotia suspended the doctor's licence on an interim basis, severing the source of the prescriptions almost immediately.
The timing made the case especially charged. Ozempic had become one of the most coveted drugs in North America, its weight-loss properties driving celebrity-fuelled demand that far exceeded what manufacturers had anticipated. Canadian pharmacies were reporting shortages, and patients relying on the drug to manage type 2 diabetes were struggling to access it. The revelation that thousands of doses had been quietly diverted south struck officials as both a betrayal of domestic patients and a sign of dangerous regulatory gaps.
Duclos announced that the federal government would work with provincial counterparts to develop legal mechanisms preventing future bulk exports of essential medications. The Food and Drugs Act would be scrutinized for the loopholes that had made the scheme possible. Assistant deputy ministers from across the country convened to seek not just an immediate fix but durable protections for Canada's domestic drug supply.
The case exposed an uncomfortable truth: a single licensed physician, operating from abroad, could write prescriptions in bulk; pharmacies, acting in good faith, would fill them; and the postal system would carry them across the border — all without triggering any alarm until provinces happened to compare notes. For Canadians waiting on Ozempic, the government's response offered some reassurance, but the episode made plain that in a continental healthcare market where demand outpaces supply, protecting domestic access may require legal tools that do not yet fully exist.
A doctor licensed to practice in Nova Scotia but based in Texas had orchestrated something that caught the attention of Canada's federal health minister: the systematic export of thousands of doses of Ozempic across the border. Over three months, the physician wrote 17,000 prescriptions for the diabetes and weight-loss drug. Two pharmacies in British Columbia filled them. The medication was then mailed to American residents—a flow of pills that Jean-Yves Duclos, Canada's health minister, would later describe as an "outrageous" abuse of the system.
The scale of the operation became clear when provincial and federal officials began comparing notes. B.C. Health Minister Adrian Dix and his counterparts in Nova Scotia flagged the pattern and moved quickly. Within days of discovering the prescriptions, they had coordinated a response. The College of Physicians and Surgeons of Nova Scotia suspended the doctor's licence on an interim basis, effectively halting the source of the prescriptions.
What made this case particularly urgent was the context in which it occurred. Ozempic, a medication originally developed for type 2 diabetes, had become one of the most sought-after drugs in North America. Its weight-loss effects had made it a status symbol among celebrities and the wealthy, driving demand far beyond what the drug's manufacturers had anticipated. Pharmacies across Canada were reporting shortages. Patients who needed the medication for its intended purpose—managing blood sugar levels—were struggling to find it. The idea that thousands of doses were being diverted south of the border, sold to American patients willing to pay premium prices, struck officials as both a betrayal of Canadian patients and a sign that the regulatory system had gaps.
Duclos signaled that the federal government would not treat this as an isolated incident. He announced that he was working with provincial health ministers to develop legal mechanisms that would prevent mass exports of essential medications in the future. The Food and Drugs Act, the primary legislation governing pharmaceuticals in Canada, would be examined for ways to close the loopholes that had allowed this scheme to operate. Assistant deputy health ministers from both federal and provincial governments convened to discuss not just the immediate crisis but permanent solutions that would protect Canada's domestic supply of high-demand drugs.
The case raised uncomfortable questions about how easily a single licensed physician could circumvent the system. A doctor with credentials in one province could practice from another country and write prescriptions in bulk. Pharmacies, following the prescriptions as written, had filled them. The mail system had carried them across the border. It took a coordinated effort between provinces to even notice what was happening. Now, officials were tasked with finding ways to tighten those connections without creating barriers that would prevent legitimate prescriptions from being filled or exported when appropriate.
For Canadians waiting for Ozempic, the discovery offered some reassurance that their government was paying attention. But it also underscored a larger vulnerability: in a continental healthcare market where drugs move freely and demand far outpaces supply, protecting access for domestic patients requires constant vigilance and legal tools that may not yet exist.
Citações Notáveis
The level of abuse was outrageous— Jean-Yves Duclos, Canada's federal health minister
A Conversa do Hearth Outra perspectiva sobre a história
How does a doctor based in Texas even get a licence to write prescriptions in Nova Scotia?
That's the gap that made this possible. He held a valid licence there, which gave him the legal authority to write prescriptions. There's no requirement that he physically practise in the province or even be present in Canada. The system assumes good faith.
And the pharmacies just filled 17,000 prescriptions without questioning it?
They were following the law. A valid prescription from a licensed physician is a valid prescription. The pharmacies had no way to know—or perhaps no obligation to know—that the prescriptions were part of a scheme to export the drug in bulk.
Why does Ozempic matter so much that this became a federal crisis?
It's not just the drug itself. It's the scarcity. Ozempic was designed for diabetics, but it became famous for weight loss. Demand exploded. Canadian patients who actually need it for blood sugar control can't find it. When thousands of doses leave the country, it makes the shortage worse for them.
So this was profitable for someone?
Very much so. American patients pay far more for Ozempic than Canadians do. The doctor, the pharmacies, whoever was coordinating the export—there was money in it. That's what made it worth the risk.
How do you stop this without breaking the system?
That's what they're trying to figure out now. You can't just ban exports—legitimate ones happen. You can't require pharmacies to police every prescription. But you can probably create flags for unusual patterns: a single prescriber writing thousands of doses, all going to one address, all being exported. The law just needs to catch up to what happened.